Inflammasome and cytokine blocking strategies in autoinflammatory disorders
Copyright © 2013 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 147(2013), 3 vom: 03. Juni, Seite 242-75 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2013
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Research Support, Non-U.S. Gov't Review Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antirheumatic Agents Inflammasomes Interleukin 1 Receptor Antagonist Protein Interleukin-1 NF-kappa B p50 Subunit mehr... |
| Zusammenfassung: | Copyright © 2013 Elsevier Inc. All rights reserved. Autoinflammatory disorders are characterized by usually unprovoked recurrent episodes of features of inflammation caused by activation of the innate immune system. Many autoinflammatory disorders - the monogenetic defects in particular - are associated with alterations of inflammasomes. Inflammasomes are complex multimolecular structures, which respond to "danger" signals by activation of cytokines. Among these, IL-1 is the key player of the innate immune response and inflammation. Consequently, IL-1 blocking strategies are specific pathway targeting therapies in autoinflammatory diseases and applied in CAPS, colchicine-resistant FMF, TRAPS, HIDS and DIRA. A number of rare genetic disorders involve inflammasome malfunction resulting in enhanced inflammatory response. IL-1 inhibition to date is the most successful specific therapy in autoinflammatory disorders. Here, current treatment strategies in autoinflammatory disorders are reviewed with a focus on inflammasome and cytokine inhibition |
|---|---|
| Beschreibung: | Date Completed 20.08.2013 Date Revised 16.11.2017 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2013.04.008 |